Building of a Diagnostic/Prognostic Database for Human ERG Variant Effects

Status Recruiting

Clinical Trial Summary

Cardiac channelopathies induce severe heart rhythm or conduction disorders. Mutations of the KCNH2 gene, that encodes the human (h) ERG channel, is responsible for 30-40% of all cases of long QT syndrome (inherited LQT2). Besides, hERG is frequently responsible for off-target effects of several pharmacological agents (acquired LQT2). With the advent of Next Generation Sequencing, hundreds of new KCNH2 variants are accumulating in regional databases including those developed by french centers of references. Worldwide, we estimate there are more than 1000 variants for hERG channel. Unfortunately, many of these new variants appear to be of unknown functional significance in spite of available clinical and genetic information. Little is known on whether they affect the channel biophysical properties, its expression at the cell surface and/or its structure. Yet, this information is crucial to determine the real degree of pathogenicity of these variants, and therefore to make the proper diagnosis on inherited LQT2, counsel the patient for his treatment and improve the management of the patient's life. Our ambition is therefore to tackle this issue of variant significance by (i) launching a large-scale multi-functional evaluation of hERG variants, (ii) introducing for the first time a formatted large-scale pathogenicity annotation score for all variants that have been functionally evaluated by this multi-parametric approach, and (iii) regrouping all the relevant information collected in every French Regional centers of reference into a single National database hosted by an infrastructure that possesses enough flexibility for continuous data implementation and cross-referencing. The database will integrate the latest International guidelines for functional pathogenicity annotation. This project will also include the pharmacological characterization of several drugs susceptible to produce acquired LQT2 with variable severities. We aim to understand whether there are structural regions within hERG channel in which the introduction of a variant is more prone to increase the risk of acquired LQT2 or if, on the contrary, a set of variants may relatively protect some patients against LQT2-inducing drugs.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Long QT Syndrome

Clinical Trial Details

NCT number	NCT06087367
Study type	Observational
Source	Nantes University Hospital
Contact	Vincent Probst, PUPH
Phone	0240165279
Email	vincent.probst@chu-nantes.fr
Status	Recruiting
Phase
Start date	September 20, 2021
Completion date	March 24, 2025

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04169100` - Novel Form of Acquired Long QT Syndrome	Phase 4
Completed	`NCT01648205` - Long-term Efficacy Study of Sodium Channel Blocker in LQT3 Patients	Phase 2
Recruiting	`NCT04675788` - Novel Approaches for Minimizing Drug-Induced QT Interval Lengthening	Phase 4
Completed	`NCT05759962` - Phase 1 Study of LQT-1213 in Healthy Adults	Phase 1
Enrolling by invitation	`NCT05903313` - A Study to Evaluate Accuracy and Validity of the Chang Gung ECG Abnormality Detection Software
Terminated	`NCT02439645` - A Registry to Determine the Clinical and Genetic Risk Factors for Torsade De Pointes
Recruiting	`NCT00221832` - Molecular Genetic Screening and Identification of Congenital Arrhythmogenic Diseases	N/A
Completed	`NCT04706104` - QT Measurement Techniques and Anesthesia Management
Recruiting	`NCT04336644` - Continuous Versus Intermittent cARdiac Electrical moNitorinG	N/A
Recruiting	`NCT02814981` - Hydroxyzine and Risk of Prolongation of QT Interval	N/A
Completed	`NCT02425189` - The Canadian National Long QT Syndrome Registry
Completed	`NCT02876380` - Prospective Identification of Long QT Syndrome in Fetal Life
Completed	`NCT00399412` - ECG Signal Collection From Long QT Syndrome, Wide QRS Complexes, Heart Failure, and Cardiac Resynchronization Patients	N/A
Completed	`NCT02513940` - Influence of Testosterone Administration on Drug-Induced QT Interval Prolongation and Torsades de Pointes	Phase 4
Completed	`NCT02441829` - Pharmacokinetics of Eleclazine in Adults With Normal and Impaired Renal Function	Phase 1
Completed	`NCT03182777` - Safety of Local Dental Anesthesia in Patients With Cardiac Channelopathies	N/A
Completed	`NCT01849003` - Study of the Effect of GS-6615 in Subjects With LQT-3	Phase 1
Completed	`NCT00316459` - Study Evaluating the Effects of Multiple Oral Doses of ERB-041 on Cardiac Repolarization in Healthy Subjects	Phase 1
Completed	`NCT00292032` - Registry of Unexplained Cardiac Arrest
Recruiting	`NCT05348564` - Comparing Direct vs Indirect Methods for Cascade Screening	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Building of a Diagnostic/Prognostic Database for Human ERG Variant Effects — CarDiag

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms